Can TROP2 ADCs reshape first-line NSCLC after Kelun-Biotech’s OptiTROP-Lung05 win?
A TROP2 ADC just pushed past pembrolizumab alone in first-line lung cancer. See why OptiTROP-Lung05 matters now.
Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer
Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.
Inhibrx’s HexAgon study may test whether smarter OX40 design can beat old failures
OX40 biology has promised more than it proved. Inhibrx now needs INBRX-106 to show pembrolizumab can work harder in HNSCC.
Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market
ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.
How AIM ImmunoTech Inc. is positioning Ampligen to overcome checkpoint inhibitor resistance in ovarian cancer
Can AIM ImmunoTech Inc.’s Ampligen improve checkpoint inhibitor responses in ovarian cancer? Explore the Phase 2 findings and implications.
STK-012 shows promise in resistant lung cancer biology, but can Synthekine deliver in Phase 2?
Synthekine’s STK-012 showed encouraging AACR 2026 data in resistant NSCLC. Read what the results could mean for frontline lung cancer treatment.
Can Immutep Limited convert orphan designation into a credible late-stage oncology program?
FDA orphan drug designation gives Immutep Limited a new sarcoma pathway. Find out why eftilagimod alfa could reshape its oncology strategy.
Why Anixa Biosciences’ Phase 2 breast cancer vaccine push matters more than the manufacturing deal itself
Anixa Biosciences is advancing its breast cancer vaccine toward Phase 2 after positive Phase 1 data. Read what this means for oncology watchers.
How Agilent’s PD-L1 companion diagnostic now shapes pembrolizumab access in esophageal carcinoma
FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx for esophageal and GEJ carcinoma, marking the eighth companion diagnostic indication alongside pembrolizumab. Read the analysis.
Can Synthekine’s STK-012 overcome immunotherapy resistance in first-line NSCLC patients?
Can STK-012 overcome immunotherapy resistance in lung cancer? Explore AACR 2026 data and what it means for IL-2 precision therapies.